Publication
Resistant mutations in CML and Ph(+)ALL - role of ponatinib.
Authors not recorded
Biologics2014PMID 25349473PMC4208348stubpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (5)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 5
- cancerChronic Myeloid Leukemia, BCR-ABL1 Positivecivic_curation1.00
- drugPonatinibcivic_curation1.00
- geneABL1civic_curation1.00
- variantABL1 Fusioncivic_curation1.00
- variantABL1 T315Icivic_curation1.00
Curated evidence
Evidence citing this paper (1)
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 25349473
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| ABL1 T315I + ABL1 Fusion1 | ||||||||
| Ponatinib | Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS | Predictive | B | Supports Sensitivity Response | 5 | accepted | EID639Ponatinib has shown to be effective in patients with BCR-ABL kinase domain mutations including T315I. PMID 25349473 · Miller et al., 2014 · Open in CIViC | civic |